炎琥宁注射液治疗手足口病疗效评价的Meta分析

Meta-analysis of Randomized Controlled Trials Yanhuning Injection for Treatment of Hand-foot-mouth Disease

目的:系统评价炎琥宁注射液治疗手足口病的临床疗效与安全性。方法:检索Cochrane Library,EBSCO,EMbase,Pub Med,CBM,VIP,CNKI和Wanfang Data数据库,查找有关炎琥宁治疗手足口病的随机对照试验(RCT),检索时限均从建库至2014年10月;按纳入与排除标准独立筛选文献、提取资料和评价质量后,采用Rev Man 5.3软件进行Meta分析。结果:共纳入51个RCT,病例共7 718例。Meta分析结果显示:炎琥宁注射液组或炎琥宁联合利巴韦林组在总有效率、患者退热时间、疱疹消退时间以及溃疡消退时间比单用利巴韦林更具有优势,其差异具有统计学意义。在安全性方面,使用炎琥宁注射液不良反应发生率为2.48%,略低于利巴韦林对照组2.57%。结论:炎琥宁注射液治疗手足口病有较好的疗效并且不良反应发生率较低。但因纳入文献总体质量较差,尚需设计更加严谨的多中心、大样本的随机对照试验进一步证实结论。

Objective： To system atically review the effective ness and safety of Yanhuning for curing the hand-foot-mouth disease （HFMD）. Method： Methods included a structured search strategy on The Cochrane Library, EBSCO, EMbase, PubMed, CBM, VIP, CNKI and Wanfang Data data bases; randomized controlled trial （RCT） of HFMD relevant Yanhuning treatment of search, were searched from inception to 2014 October; according to the inclusion and exclusion criteria in dependent screening literature, data extraction and quality assessment, Meta-analysis was carried out using Rev Man 5.3 software. Result： 51 RCT were included, 7 718 cases. Results showed that： Yanhuning or Yanhuning combined Ribavirin group＇s efficiency in patients with fever, total time, ulcers resolve time have more advantages than single Ribavirin, with statistical difference. In the aspec to fsafety, Yanhuning injection group, the incidence rate of adversea ction was 2.48% , slightly lower than the Ribavirin group 2.57%. Conclusion： Yanhuning injection in the treatment of HFMD has good curative effect and low incidence rate of adverse action. But because of the overall poor quality into literature, RCT is needed to design multi center, large sample of more rigorous further confirmed the conclusion.